Skip to content

Anne M Landau

Translational Neuropsychiatry Unit, Aarhus University, Denmark; Department of Nuclear Medicine and PET Center, Aarhus University and Hospital, Denmark.

2 papers in the library · 7 citations · publishing 2024-2025

Papers

Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression.

Pharmacological research January 1, 2025 Nicole R Silva, Shokouh Arjmand, Luana B Domingos et al. 6 citations

In a rat model of depression (Flinders Sensitive Line), depressive behavior was negatively correlated with levels of the endocannabinoid 2-AG. A single dose of S-ketamine restored 2-AG levels and increased endocannabinoid signaling in the prefrontal cortex. Although S-ketamine decreased gene expression of the CB1 receptor and the enzyme FAAH, protein levels did not change significantly. S-ketamine increased CB1 receptor binding, and computer modeling suggested it may bind to CB1, CB2, GPR55, and FAAH. However, blocking CB1 receptors with rimonabant did not prevent S-ketamine's behavioral effects, indicating a complex interaction with the endocannabinoid system that requires further study.

Subanesthetic S-ketamine does not acutely alter striatal dopamine transporter binding in healthy Sprague Dawley female rats.

Synapse (New York, N.Y.) July 1, 2024 Simone Larsen Bærentzen, Jakob Borup Thomsen, Majken Borup Thomsen et al. 1 citation

Acute administration of S-ketamine, a fast-acting antidepressant, did not alter dopamine transporter (DAT) availability in the striatum of healthy female rats, as measured by [18F]FE-PE2I PET imaging and [3H]GBR-12935 autoradiography. This negative result suggests that changes in DAT binding are not involved in S-ketamine's rapid antidepressant mechanism, though further research is needed.